Working… Menu

Plasma RBP Levels in Patients With Idiopathic Hypogonadotrophic Hypogonadism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01758094
Recruitment Status : Completed
First Posted : January 1, 2013
Last Update Posted : January 3, 2013
Information provided by (Responsible Party):
Aydogan Aydogdu, Gulhane School of Medicine

Brief Summary:
The aim of the present study was to demonstrate the RBP4 levels, association of RBP4 with insulin resistance and influence of testosterone treatment on this cytokine in patients with idiopathic hypogonadotropic hypogonadism.

Condition or disease Intervention/treatment
Idiopathic Hypogonadotropic Hypogonadism Drug: Sustanon 250 mg ampule (Testosterone esters)

Layout table for study information
Study Type : Observational
Actual Enrollment : 25 participants
Observational Model: Case-Control
Time Perspective: Prospective
Study Start Date : January 2008
Actual Primary Completion Date : August 2012
Actual Study Completion Date : August 2012

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Hypogonadotropic hypogonadism patients
Treatment naive 25 patients with idiopathic hypogonadotrophic hypogonadism
Drug: Sustanon 250 mg ampule (Testosterone esters)
Drug used for treatment of hypogonadism
Other Name: No name

Primary Outcome Measures :
  1. Retinol binding protein 4, hs-CRP levels in patients with idiopathic hypogonadotrophic hypogonadism [ Time Frame: 2008-2012 ]

Secondary Outcome Measures :
  1. Effect of testosterone treatment on retinol binding globulin 4 and hs-CRP levels in patients with hypogodotrophic hypogonadism [ Time Frame: 2008-2012 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 26 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients with hypogonadotrophic hypogonadism

Inclusion Criteria:

decreased serum testosterone concentration below the normal range (serum T < 300ng/dL), FSH and LH levels within or below the normal range, absence of a pituitary or hypothalamic mass lesions on MRI, presence of gonadotropin response to repetitive doses of GnRH, normal smell test and normal karyotypes

Exclusion Criteria:

previous androgen treatment, history of smoking, presence of bilateral anorchia, intellectual deficiency, diabetes mellitus, arterial hypertension or dyslipoproteinemia, medication of any kind and drug abuse. Because of possible confounding effects, patients with other hormone deficiencies were excluded.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01758094

Layout table for location information
Gulhane School of Medicine Dep. of Endocrinology and Metabolism
Ankara, Turkey, 06018
Sponsors and Collaborators
Gulhane School of Medicine
Layout table for investigator information
Study Director: Aydogan Aydogdu, MD Gulhane School of Medicine, Department of Endocrinology and Metabolism
Layout table for additonal information
Responsible Party: Aydogan Aydogdu, MD, Gulhane School of Medicine Identifier: NCT01758094    
Other Study ID Numbers: 24122012
First Posted: January 1, 2013    Key Record Dates
Last Update Posted: January 3, 2013
Last Verified: January 2013
Keywords provided by Aydogan Aydogdu, Gulhane School of Medicine:
Retinol binding globulin 4
Testosterone treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Gonadal Disorders
Endocrine System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs